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Abstract
Background: Reciprocal interactions between glial cells and olfactory receptor neurons (ORNs) cause ORN axons entering
the brain to sort, to fasciculate into bundles destined for specific glomeruli, and to form stable protoglomeruli in the
developing olfactory system of an experimentally advantageous animal species, the moth Manduca sexta. Epidermal growth
factor receptors (EGFRs) and the cell adhesion molecules (IgCAMs) neuroglian and fasciclin II are known to be important
players in these processes.
Methodology/Principal Findings: We report in situ and cell-culture studies that suggest a role for glycosphingolipid-rich
membrane subdomains in neuron-glia interactions. Disruption of these subdomains by the use of methyl-b-cyclodextrin
results in loss of EGFR activation, depletion of fasciclin II in ORN axons, and loss of neuroglian stabilization in the membrane.
At the cellular level, disruption leads to aberrant ORN axon trajectories, small antennal lobes, abnormal arrays of olfactory
glomerul, and loss of normal glial cell migration.
Conclusions/Significance: We propose that glycosphingolipid-rich membrane subdomains (possible membrane rafts or
platforms) are essential for IgCAM-mediated EGFR activation and for anchoring of neuroglian to the cytoskeleton, both
required for normal extension and sorting of ORN axons.
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Introduction
Many types of neuron-glia interactions are known to be critical in
the creation of complex neural architectures. In the primary
olfactory pathway of the moth Manduca sexta, neuron-glia interac-
tions have been shown to underlie glial cell proliferation and
migration, the guidance and sorting of olfactory receptor axons
(ORNs) as they grow from the antenna toward and into their target
region of the brain, and the construction of olfactory glomeruli after
the axons reach that target [1–4]. Evidence for neuron-glia
interactions is strong in other developing olfactory systems as well
[3,5–8],suggesting thattheyhave broadimportanceforthecreation
of olfactory circuitry. Since the cellular details of the olfactory
neuron-glia interactions differ slightly in different species and are so
well characterized in developing M sexta, we seek to elucidate the
underlying molecular interactions in this species as the basis for a
thorough understanding of the bidirectional conversation between
neurons and glial cells in the establishment of a complex neuropil.
We have adduced evidence for the involvement of a number of
molecules in neuron-glia communication in the developing
olfactory pathway of Manduca, including two receptor tyrosine
kinases (RTKs) - epidermal growth factor receptors (EGFRs) and
fibroblast growth factor receptors (FGFRs) - and two cell adhesion
molecules of the Ig superfamily (IgCAMs) - neuroglian and
Manduca fasciclin II [4,9–10; Gibson, unpublished]. Taken
together with relevant results in other systems [11–18], our studies
indicate that RTKs and IgCAMs are strong candidates to underlie
axon-glia interactions involved in ORN axon outgrowth, sorting,
fasciculation and subsequent glomerulus development.
As part of our study of IgCAM-EGFR interactions in the
developing olfactory pathway, we investigate here the possibility
that this signaling interaction is influenced by the association of
these molecules with membrane rafts. Membrane rafts (formerly
referred to as lipid rafts; [19]) and platforms (larger aggregates of
rafts) are transient membrane subdomains enriched in sphingomy-
elin, glycosphingolipids (GSLs), and sterols [20–24]. They serve as
platformsforthe localization and aggregationofmolecularpartners,
modulating their function by clustering signaling partners in close
proximity or, in some cases, by keeping them separated (see [25–28]
for reviews). They also place signaling molecules in proximity to
their downstream effectors. IgCAMs and RTKs (EGFRs in
particular) are known to be associated with membrane rafts in a
number of systems and the function of RTKs appears to be
modulated by that association [29–39].
In Ms e x t a , ORN axons include a significant glycosphingolipid
(GSL) fraction in both the developing and adult olfactory systems
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growing literature describing the ability of rafts to modulate receptor
tyrosine kinase activation and IgCAM interactions [29–39,41] led us
to ask if the GSLs we had detected on ORN axons are components
of membrane rafts which, in turn, could serve to modulate the
EGFR and IgCAM interactions that have been implicated in several
steps of development of the olfactory pathway [4].
As a step in dissecting the molecular bases of neuron-glia
interactions critical in the formation of an olfactory pathway, we
describe here studies designed to characterize the RTK and
IgCAM relationships specific to axonal membrane rafts. Under-
standing which molecules are associated with these membrane
subdomains also will serve to implicate particular signaling
cascades that can be studied further. Our results indicate that
pharmacological disruption of glycosphingolipid-rich membrane
subdomains (possible membrane rafts or platforms) interferes with
both EGFR activation and IgCAM stabilization that are essential
for normal development of glomeruli.
Materials and Methods
Animals
Manduca sexta (Lepidoptera: Sphingidae) were reared from eggs
on an artificial diet in a laboratory colony as described by Sanes
and Hildebrand [42]. The adult antennal system develops during
metamorphosis, when the larva advances through the pupal phase
to become an adult moth. The pupal phase can be divided into 18
stages, each lasting 1–4 days. Pupae were staged according to
features, such as eye pigmentation and leg development, visible
through the cuticle under fiber-optic illumination as described by
Tolbert et al. [43] and Oland and Tolbert [44].
Preparation of cultures
Explants of olfactory receptor epithelium. Whole
antennae were removed from the troughs of cuticle in which
they develop in stage-4 female pupae; explants were prepared as
described in Tucker et al. [45], except that enzymatic digestion
was done at 37uC for 4 min in a Ca
2+- and Mg
2+-free Hanks’
balanced salt solution (21250–014; Gibco, Grand Island, NY)
containing 22.5 mg/ml Liberase Blendzyme 1 (Roche,
Indianapolis, IN). Miniwell culture dishes were made as
described previously [46]. After plating of explants, culture
dishes were sealed with strips of Parafilm to prevent evaporation
and incubated in a 26uC humidified incubator with room air.
Removal of olfactory receptor neurons
In some animals, the primary olfactory center of the brain, the
antennal lobe, was deprived of ORN axon input throughout
development by removing the developing antenna using surgical
methods described previously [44,47]. Because ORN axons, with
their cell bodies in the antennae, do not project contralaterally, the
antennal lobe on the operated side received no input from ORNs
[47,48], but did receive normal input from the receptor neurons in
the labial palp pit organ, which terminate in a single, readily
identified glomerulus in the ventromedial part of the antennal lobe
[49,50]. The unoperated side served as the control.
In situ depletion of membrane sterols with methyl-b-
cyclodextrin (MbCD)
In females at early stage 2 or 3, insect saline alone (controls) or
insect saline with MbCD (Sigma, #C-4555, 150 mg/ml) was
injected into the headspace anterior to the brain. The injection
sites were sealed with melted dental wax, and the animals were
returned to the rearing room and allowed to develop to the desired
stage.
In vitro depletion of membrane sterols with MbCD
Explants were cultured for 6 hours, then treated with culture
medium alone or culture medium plus MbCD (added at100 mM
in doses to give final concentrations of 0, 0.5, 1, 1.5, and 2 mM).
The cultures were incubated for an additional 24 hours, then
processed for WGA and anti-horseradish peroxidase immunocy-
tochemistry, or for anti- EGFR, neuroglian, or fasciclin II
immunocytochemistry, (described below). Cells exposed to MbCD
at these levels exhibited no significant signs of cytotoxicity.
Primary antibodies for immunocytochemistry
Neuroglian. Mouse monoclonal antibody 3B11 against the
extracellular Ig domains of M sexta neuroglian [51–54] was the
generous gift of Dr. James Nardi, University of Illinois, Urbana,
IL.
M sexta Fasciclin II. Mouse monoclonal antibody P1E1-
1C3 (‘‘C3,’’ [10,55]), developed against the extracellular domain
common to all isoforms of M sexta fasciclin II (MFas II), and guinea
pig polyclonal antibodies specific for an extracellular region of the
GPI-linked isoform of fasciclin II (GPI-FasII) and an intracellular
region of the transmembrane isoform of fasciclin II (TM-FasII)
[10] were the generous gifts of Dr. Philip Copenhaver, Oregon
Health Sciences University, Portland, OR.
EGFR. We previously have shown that an antibody to a
highly conserved region of the human ErbB-1 protein (#ab62,
Abcam, Cambridge, MA) and an antibody to activated human
EGFR (phosphorylated at tyrosine residue 845; #2231, Cell
Signaling Technology, Beverly, MA) could be used to recognize
the M sexta EGFR and the activated EGFR respectively [4,56].
These antibodies to cytoplasmic EGFR domains were used on
Vibratome sections of fixed, Triton-permeabilized brains. For
immunocytochemistry of ORN cultures we used antibodies to
extracellular regions of the EGFR from Drosophila melanogaster
(Santa Cruz Biotechnology, Santa Cruz, CA; #sc-15827 and
Abcam #ab49966) in order to avoid using Triton, which would
have disrupted possible rafts. These antibodies bind to EGFRs
regardless of activation state.
Horseradish peroxidase (HRP). A rabbit polyclonal
antibody to HRP (Jackson Immunoresearch, West Grove, PA, #
323-005-021) was used as a general marker for cultured neurons
[57].
Ankyrin B. A mouse monoclonal antibody generated against
a peptide corresponding to the spectrin-binding domain of human
ankyrin B was purchased from Zymed Laboratories ((#33-3700,
Invitrogen). In M sexta, this antibody recognizes a subset of ORN
axons targeting a single glomerulus located dorso-posteriorly in the
antennal lobe. It is used here as a marker for this axonal subset
(not as a means of monitoring ankyrin B expression).
In situ: immunocytochemistry
Pupae of various stages of development were anesthetized by
cooling on ice. Brains (female, except for lectin labeling of adult
male brains) were dissected under insect saline solution
(150 mM NaCl, 4 mM KCl, 6 mM CaCl2, 10 mM HEPES,
5 mM glucose, pH 7.0, adjusted to 360 mOsm with mannitol;
[58]). The perineurial sheath covering the brain was removed to
aid in fixative and antibody penetration. The final step in all
protocols, unless noted, was clearing the brains or sections for
15 min each first in 50% glycerol in water, then in 80% glycerol in
water, and finally mounting on slides in 80% glycerol.
Membrane Lipid Domains
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fixed on a shaker overnight (ON) at 4uC in 4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4, or in methanol/37% formalin (9:1)
at 220uC overnight. Vibratome (Technical Products International,
St. Louis, MO) sectioning and immunocytochemistry were performed
as previously described [4].
EGFR and activated EGFR (pEGFR). The fixation protocol
of Sinakevitch et al. [59] was used. Briefly, brains were dissected
into 2.5% paraformaldehyde, 1% glutaraldehyde, 1% sodium
metabisulfite in 0.1 M cacodylate buffer, pH 7.2, microwaved
with a Pella research-grade oven (# 3450, with variable power
controller #3430 and cold spot) with chilling plate at 18uC and
power setting #2 for 2 min on/2 min off/2 min on/2 min off,
and then fixed overnight on a shaker at 4uC. Following sectioning,
brains were washed for 30 min in freshly prepared 0.01 M
NaBH4, 0.5% sodium metabisulfite, in 0.05 M Tris-HCl, pH 7.5.
Immunocytochemistry was performed as previously described [4].
Ankyrin B. Reproducible labeling of a unique set of ORN
axons was achieved by using a high-pH fixation protocol: dissected
brains were microwave-fixed in 50 mM carbonate buffer, pH 9.4,
containing 2.5% paraformaldehyde, 1% glutaraldehyde, and 1%
sodium metabisulfite (final pH=10.8), followed by incubation in
fixative solution ON at 4uC. Brains were embedded, sectioned,
and washed for 30 min in freshly prepared 0.01 M NaBH4, 0.5%
sodium metabisulfite, in 0.05 M Tris-HCl, pH 7.5. Sections were
incubated in Triton-containing blocking solution [Tris-
buffered saline (TBS; 20 mM Tris-HCl, 150 mM NaCl, pH 7.4)
with 0.1% Triton X-100, 0.1% sodium azide, and 1% Ig-free
bovine serum albumin (# 001-000-161, Jackson ImmunoResearch,
West Grove, PA)] for 1 hr at room temperature (RT), then anti-
ankyrin B was added at 2 ml/ml. Sections were incubated at 4uC
ON, then washed 4X30 min in TBS with 0.1% Triton (TBST) and
incubatedwithCy3-conjugated goatanti-mouseIgG+IgMantibody
(Jackson # 115-165-068) at 1:300 in blocking solution for 2 hrs at
room temperature. To amplify the signal, sections were washed and
incubated with Alexa 564-conjugated donkey anti-goat (Molecular
Probes) at 1:250 in blocking solution ON at 4uC, then washed and
further labeled with Syto 13 as described below. Controls for
nonspecific immunolabeling were no-primary controls.
In vitro: immunocytochemistry of MbCD-treated ORN
explants
In the following protocols, in order to get as accurate a picture
of molecule distribution as possible, it was necessary to use
antibodies recognizing an extracellular domain of the target
molecule, so that Triton permeabilization of the cell membranes
could be avoided.
Anti-EGFR antibody. Control and MbCD-treated explants
cultured for 30 hrs were rinsed in insect saline 3X5 min, fixed in
4% paraformaldehyde in PBS overnight at 4uC, washed 4X5 min
in TBSA, and then incubated in blocking solution (TBSA with
0.5% fish gelatin, Sigma #G7765) for 1 hr. A mouse monoclonal
antibody to an extracellular region of the D. melanogaster EGFR
(Abcam #ab49966) was added to blocking solution at 1:200.
Dishes were incubated in primary antibody solution (80 ml/dish)
overnight at 4uC in a humidified chamber, rinsed 4X5 min in
TBSA, incubated in blocking solution (80 ml/dish) containing
Cy3-conjugated goat anti-mouse IgG+IgM antibody (Jackson
#115-165-068) at 1:300 for 4 hr at RT, washed 4X5 min in
TBSA, and mounted in TBSA.
Anti-neuroglian antibody. Control and MbCD-treated
explants cultured for 30 hrs were rinsed in insect saline
3X5 min, fixed in 2% paraformaldehyde in insect saline
overnight at 4uC, washed 4X5 min in insect saline, and then
incubated in blocking solution (insect saline with 5% normal
donkey serum and 1% Ig-free bovine serum albumin) for 1 hr at
RT. Mouse anti-neuroglian (3B11) was diluted 1:1,000 in blocking
solution. Dishes were incubated in primary antibody solution
(80 ml/dish) overnight at 4uC in a humidified chamber, rinsed
4X5 min in SIS, incubated in blocking solution (80 ml/dish)
containing Alexa 488-conjugated goat anti-mouse F(ab9)2 antibody
fragments (Molecular Probes, #A11017) at 1:300 for 4 hr at RT,
washed 4X5 min in insect saline, and mounted in insect saline.
Anti-fasciclin II antibody. Control and MbCD-treated
explants cultured for 30 hrs were rinsed in insect saline
3X5 min, fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4, overnight at 4uC, washed 4X5 min in TBS, and
then incubated in blocking solution (TBS with 0.5% fish gelatin)
for 1 hr. A mouse monoclonal antibody to MFas II (C3) was added
to blocking solution at 1:5,000. Dishes were incubated in primary
antibody solution (80 ml/dish) overnight at 4uC in a humidified
chamber, rinsed 4X5 min in TBS, incubated in blocking solution
(80 ml/dish) containing Alexa 488-conjugated goat anti-mouse
F(ab9)2 antibody fragments at 1:400 for 4 hr at RT, washed
4X5 min in TBS, and mounted in TBS.
In situ: lectin labeling of whole brains
Sectioned male brains that had been fixed on a shaker ON at
4uC in 4% paraformaldehyde plus 0.15% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4, were incubated ON at 4uC in 0.5 ml
lectin buffer (300 mM NaCl, 100 mM CaCl2 in 10 mM HEPES,
pH 7.5) containing 2 ml (10 mg) each of Rhodamine-labeled wheat
germ agglutinin (WGA, Triticum vulgaris) and fluorescein-labeled
Artocarpus integrifolia lectin (Jacalin) (Vector Laboratories, Burlin-
game, CA) or Alexa-633-labeled WGA (#W21404) (Invitrogen,
Carlsbad, CA).
In vitro: lectin labeling of explants
Cultured explants of the olfactory epithelium of the antenna
were fixed in 4% paraformaldehyde with 0.1% glutaraldehyde in
0.1 M phosphate buffer, pH 7.4 for 30 min, washed in phosphate-
buffered saline (PBS), and incubated with 0.5 mg WGA-rhodamine
or WGA-Alexa 633 in 1 ml PBS for 2 hr at RT. The explants
were then washed 2X10 min in PBS, and mounted in PBS.
In vitro: combined immunocytochemistry and lectin
labeling
Lectin with anti-EGFR antibody. Explants cultured for
24 hours were rinsed in insect saline 2X5 min, fixed in 2%
paraformaldehyde in insect saline for 30 min at RT, washed
2X5 min in insect saline, and then incubated in blocking solution
(insect saline with 1% IgG-free BSA and 5% normal donkey
serum) for 1 hr. Dishes then were incubated in a mixture of goat
anti-Drosophila EGFR (Santa Cruz Biotechnology, #sc-15827) at
1:1000 and WGA-rhodamine (1:10,000) in blocking solution
(100 ml/dish) for 3 hrs at RT. Controls were incubated in blocking
solution minus antibodies or WGA. Dishes were rinsed 3X5 min
in TBS, incubated in blocking solution (100 ml/dish) containing
Cy5-conjugated donkey anti-goat antibodies (Jackson # 705-175-
147) at 1:400 for 2 hrs at RT, washed 2X5 min in TBS, and
mounted in TBS.
Lectin with anti-M sexta neuroglian or anti-M sexta
fasciclin II antibody. Explants cultured for 24 hours were
rinsed in insect saline 2X5 min, fixed in 4% paraformaldehyde
and 0.5% glutaraldehyde in TBS for 30 min at RT, washed
2X5 min in TBS, and then incubated in blocking solution (TBS
with 1% IgG-free BSA) for 1 hr. Mouse anti-neuroglian (3B11)
(1:1000) or mouse anti-MFas II (C3) (1:5000) were added with
Membrane Lipid Domains
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Controls were incubated in blocking solution minus antibodies or
WGA. Dishes were incubated in primary antibody solution
overnight at 4uC, rinsed 3X5 min in TBS, incubated in blocking
solution (100 ml/dish) containing Alexa 488-conjugated F(ab’)2
fragment of goat anti-mouse antibodies at 1:400 for 2 hrs at RT,
washed 2X5 min in TBS, and mounted in TBS.
Lectin with anti-HRP. MbCD-treated explants cultured for
30 hrs were rinsed in insect saline 2X5 min, fixed in 4%
paraformaldehyde and 0.1% glutaraldehyde in PBS for 30 min
at RT, washed 2X5 min in PBS, and then incubated in blocking
solution (PBS with 1% IgG-free BSA) for 1 hr. Rabbit anti-HRP
(1:1,000) was added with WGA-rhodamine (1:10,000) to blocking
solution (100 ml/dish). Dishes were incubated in primary antibody
solution overnight at 4uC, rinsed 3X5 min in PBS, incubated in
blocking solution (100 ml/dish) containing Alexa 488-conjugated
goat anti-rabbit antibody (Molecular Probes) at 1:400 for 1 hr at
RT, washed 2X5 min in PBS, and mounted in PBS.
Labeling of cell nuclei
To render glial-cell nuclei visible, all cell nuclei were labeled
with a DNA-specific tag (Syto 13; Molecular Probes, #S-7575) as
described previously [4]. Glial nuclei were identified by their small
size compared to neuronal nuclei and by their location either in
the axonal sorting zone region of the antennal nerve where they
are the only cell type present [9] or in the envelope surrounding
each glomerulus [44,60].
In vitro: Vybrant DiI
Explants of olfactory epithelium growing in culture were labeled
using a protocol adapted from Hering et al. [61]. Cultures were
fixed and washed as for WGA-rhodamine labeling. Vybrant DiI
(#V-22885, 1 mM in ethanol, Molecular Probes, Eugene OR), at
0.5 ml in one ml PBS was added to each dish and allowed to
incorporate into cell membranes for 20 min at RT. Cultures were
washed 2X10 min in PBS, incubated in PBS at 4uC for 24–48 hr
to allow dye diffusion within membranes, then imaged using
confocal microscopy with an upright microscope using the
hanging-drop technique. After imaging, the culture dishes were
placed on ice and 0.5% Triton in PBS (4uC) was added for 10 min
to extract the dye from non-raft membranes. Cells were washed
4X10 min in 4uC PBS on ice to remove the Triton and then re-
imaged.
Confocal microscopy and image processing
Vibratome sections. Sections were viewed on a Nikon PCM
2000 laser scanning confocal system (Nikon E800 microscope
equipped with argon, green He Ne, and red He Ne lasers) and
Simple 32 software (Compix Inc., Cranberry Township, PA) or on
a Zeiss 510 Meta equipped with argon and green and red He Ne
lasers and LSM software. Optical sections were acquired at 1- to
10-mm intervals through the depth of the antennal lobe (AL) and
saved as three-dimensional stacks. Confocal image stacks were
projected and merged in false color using Confocal Assistant
(copyrighted by Todd Brelje, distributed by Bio-Rad, Richmond,
CA) or the Zeiss LSM image browser, and then imported into
Corel Photopaint, where image hue, intensity, and contrast were
adjusted for maximum clarity. The images were then combined
into figures in Corel Draw, where annotations were added.
Tissue culture. Dishes were imaged as above, with optical
sections acquired at 0.1 to 0.3 mm intervals. In cases where
visualizing all axons or processes was needed, brightfield images
also were collected.
Counting of MFas II-positive glomeruli in control and
MbCD-treated antennal lobes
Previous studies revealed that untreated antennal lobes contain
14–21 glomeruli that label with the MFas II (C3) antibody [10]. In
the current study, the entirety of each AL was sectioned at 100-mm
intervals with a Vibratome and imaged. Each labeled glomerulus
was followed through the section and between sections, if
necessary, resulting in a count of MFas II-labeled glomeruli.
Inhibition of EGFR activity
The effects of the highly selective, cell-permeable EGFR
inhibitor PD168393 [62] (#513033, Calbiochem, La Jolla, CA;
IC50 =700 pM) on AL development have been described
previously [4]. We injected PD168393 (250 or 500 mmol in 5 or
10 ml DMSO) or DMSO alone into the headspace at early stage 5
of adult development. The animals were then returned to the
incubator and allowed to develop until they reached stage 7.
Sucrose step-gradient flotation of detergent resistant
membranes
Brains from 24 animals at stages 6 and 7 (12 each male and
female) were stripped of their perineureum. Antennal lobes and
attached nerves were removed from the dissected brains so that
they could be processed and evaluated separately from the rest of
the brain. Separation of Triton soluble and Triton-resistant
fractions was performed basically as previously described [63],
with several modifications: 1) tissue was homogenized directly after
dissection to avoid possible artifacts resulting from freezing; 2)
homogenization buffer included phosphatase inhibitors (Sigma
P5726) in addition to protease inhibitors (Sigma P2714); 3)
additional gradient steps (25 and 35%) flanking the 30% step were
added to better distinguish the Triton-resistant fractions because
previous work [63; Gibson, unpublished] revealed that the 30%
sucrose fraction contained the components common to membrane
rafts, while the 40 and 60% fractions contained the Triton-soluble
membranes and associated proteins; 4) buoyant fractions were
demarcated and collected based on presence or absence of
material made visible by light scattering, rather than by fixed
volume. The 40 and 60% sucrose fractions were pooled.
Immunoblotting of gradient fractions
Proteins from the sucrose gradient fractions were precipitated
with 220uC acetone, resolubilized in SDS-PAGE loading buffer
containing protease and phosphatase inhibitors, separated via
SDS-PAGE, and transferred to PVDF membranes as described
previously [4,10,63]. One fourth of the total protein collected
(corresponding to 12 ALs with attached nerves) was loaded in a
given lane. Immunoblots using antibodies to pEGFR, M sexta
neuroglian, and the transmembrane and GPI-linked isoforms of M
sexta fasciclin II were performed as described [4,10,63].
Results
The following brief description of the olfactory pathway will
provide orientation to the adult and developing pathways in M
sexta. In the adult moth [3,64,65], ORN axons extend from cell
bodies in the sensory epithelium of the antennae through the
antennal nerve to their target glomeruli in the AL, entering the
glomeruli from the nerve layer that lies external to the glomerular
layer. Within the glomeruli, the ORN axons synapse with the
dendrites of AL neurons whose cell bodies lie entirely outside of
the neuropil, mainly in two major clusters. Each glomerulus is
almost completely surrounded by an envelope of glial cells and
Membrane Lipid Domains
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around a coarse central neuropil composed of AL neuron
dendrites. Output neurons of the AL send their axons via discrete
tracts to higher order centers in the brain.
Development of the primary olfactory pathway of the moth
occurs during the metamorphosis from larva to adult. Metamor-
phosis can be divided into 18 stages, each roughly a day in length
[44]. ORN axons navigate toward the AL and induce the
proliferation of glial cells in the entry region of the nerve at stage 4
(Fig. 1B). These glia then migrate into the base of the nerve, where
they populate an axon sorting zone (SZ) during stages 5 through 7
(Fig. 1C–E). Later axons growing in from the antenna dramat-
ically change their trajectories when they enter this glia-rich SZ,
sorting into fascicles destined for individual glomeruli or subsets of
glomeruli in particular regions of the AL [9]. Once in their target
region, the axon terminal branches form round ‘‘protoglomeruli’’
during stages 5 and 6, and the array of protoglomeruli serves as the
template for the mature glomerular array that is constructed
during stages 6 through 9 (Fig. 1D–F) [66,67]. Neuropil glial cells
migrate between protoglomeruli and extend processes to stabilize
the protoglomeruli, as the dendrites of AL neurons grow in and
begin participating in synapses at stage 7 [68].
Identification of GSL-rich membrane subdomains and
associated molecules on ORN axons
As a first step in determining whether interaction among the
signaling molecules implicated in developmental events in the
olfactory pathway of M sexta could be modulated by inclusion in or
exclusion from rafts, we sought to determine the pattern of
membrane rafts on ORN axons.
Previous experiments [40,63] established the presence of
detergent-resistant membranes containing GSLs, sphingomyelins,
and a GPI-linked protein, all characteristic components of
membrane rafts, in developing (stage-7) brains of M sexta.W e
also have shown in M sexta that WGA labels one or more GSLs on
ORN axons in fixed brain sections [40].Because GSLs are known
to be concentrated in membrane rafts, we used WGA as a probe
for rafts.
To allow resolution at the level of single axons, we used WGA to
label axons extending from explants of the antennal sensory
epithelium from stage-4 animals that had been cultured for 24–
48 hr. WGA labeling appeared in the cell bodies and along the
length of the ORN axons and into their growth cones, including
the filopodia. The axons displayed patchy labeling, consistent with
localization of these GSLs to subdomains of axonal plasma
membranes (Fig. 2A, B). The sizes of the patches varied from
approximately 0.3 to 1.4 mm. Rafts are now defined to have
diameters of just 10–200 nm (Keystone Symposium on Lipid Rafts
and Cell Function; [19]), but published reports of confocal
imaging studies using fluorescent raft components [69] report sizes
(,1 mm) similar to those found here and likely reflect amplification
of apparent size by attachment of multiple fluorescent molecules
and/or aggregation of smaller raft domains.
To test the hypothesis that the WGA-labeled (and therefore
GSL-rich) patches were membrane rafts or raft aggregates, we
used an additional technique, described by Hering et al. [61],
which takes advantage of the operational definition of rafts as
membrane subdomains that are resistant to extraction by Triton
X-100 at 4uC [21–23]. Cultured neurons were fixed and labeled
with Vybrant DiI, a lipophilic dye, followed by extraction of the
dye from most phospholipid moieties (but not from detergent-
resistant membrane subdomains) with Triton X-100 at 4uC. The
resulting patchy labeling (Fig. 2C, C9) is similar to that seen for
WGA labeling. In preparations doubly labeled with Vybrant-DiI
and WGA, the WGA was always co-localized with Vybrant DiI
patches (Fig. 3A–C), suggesting that the GSLs previously shown to
be ligands for WGA are indeed components of membrane
subdomains compositionally similar to rafts. Not all of the Vybrant-
DiI patches were associated with WGA, however (Fig. 3C), possibly
indicating that the ORN axons have multiple membrane
subdomains of different lipid composition that house different
molecular species, as has been found in several vertebrate cell
types [70–75]. Because of the difficulty inherent in proving the
existence and characteristics of membrane rafts in cell membranes
[69], we will simply refer to the detergent resistant, GSL-rich
patches seen in our ORN explant cultures as glycosphingolipid-
rich membrane subdomains (gMSDs).
We then asked whether IgCAMs and/or EGFRs co-localized
with the gMSDs described above. Aldehyde-fixed (see Methods
section) 24–48 hr ORN explant cultures were labeled with WGA-
rhodamine, as a gMSD marker, and antibodies to the extracellular
domains of EGFR, neuroglian, or M sexta fasciclin II (MFas II).
EGFRs appeared to co-localize with WGA-labeled patches
(Fig. 4A). Small neuroglian-positive puncta were detected inside
most WGA-labeled patches but also in areas not labeled with
WGA (Fig. 4B). MFas II (C3) immunoreactivity was found over
most of the lengths of the axons, but infrequently in the WGA-
labeled patches (Fig. 4C). Figure 4 indicates that EGFRs may be
normally confined to WGA-labeled gMSDs, whereas neuroglian
and MFas II may be found in or out of those domains. In light of
our results with WGA-Vybrant DiI co-labeling, it is possible that
the IgCAM molecules not co-localized with WGA were associated
with other membrane subdomains which do not bind WGA, but
we were unable to test this in vitro because we were not able
technically to label for IgCAMs and Vybrant DiI-positive
detergent-resistant patches in the same preparations, and we have
found no lectin label for the gMSDs not recognized by WGA [40].
Sucrose-gradient flotation of membrane subdomains
An alternative approach to identifying molecules associated
with membrane rafts is to solubilize membranes with Triton X-
100 at 4uC, then overlay with a sucrose gradient and centrifuge at
high speed [76]. Triton-soluble membranes (phospholipid-rich)
remain at or near the bottom of the gradient, while Triton-
resistant membranes (rich in GSLs and sterols) float to a level
corresponding to their lower density [76]. Fractions can then be
collected and analyzed for components. We have previously done
this with Ms e x t abrains and found a Triton-resistant fraction
containing GSLs, sphingomyelin, and a GPI-linked protein [63].
In the current study, Ms e x t abrains were removed, antennal lobes
separated from the rest of the brains, both tissues homogenized
and subjected to Triton exposure, sucrose density flotation, PAGE
separation and immunoblotting as previously described [63]. For
the AL fractions, the pEGFR immunoblot revealed a strong band
corresponding to EGFR dimers (250 kDa) at the 30235%
interface, with weaker bands at the 25% layer and the 40+60%
(Triton-soluble) layers (Fig. 5), possibly an indication of EGFR
movement in and out of rafts, as has been shown to occur with
other RTKs [30,35,39]. The pattern for TM-Fas II resembled
that for pEGFR, while bands for GPI-Fas II were seen only in the
25% fraction and the 30235% interface, as expected for a GPI-
anchored protein [76]. Neuroglian was seen only in the 30235%
interface, suggesting that it is found only in Triton-resistant
membrane subdomains. Interestingly, similar blots performed on
fractions isolated from the remainder of the brains from which the
ALs were removed gave a different pattern, with pEGFR and
TM-Fas II labeling primarily in the 25% and the 40+60%
fractions, with stronger labeling in the latter (not shown). Labeling
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7222Figure 1. Schematic diagram of antennal lobe development in Manduca sexta. A: At stage 2 of development, prior to arrival of ORN axons
from the antennae, the nascent AL consists of a medial group (mg) of projection neurons (pn, one shown in red), a lateral group (lg) comprising local
interneurons (ln, one shown in blue), uniglomerular projection neurons, and multiglomerular projection neurons, and AL glia (small cells) surrounding
a coarse neuropil. B: The first ORN axons (green) arrive at stage 4. The axons induce a subset of glial cells to proliferate and migrate outward toward
the ingrowing axons to form a sorting zone at the base of the antennal nerve. C: By stage 5, ORN axons arriving at the sorting zone are induced to
disassociate from other axons, change course dramatically, and refasciculate with other axons targeting common glomeruli. ORN axons penetrate the
layer of glial cells, their terminal branches form glomerular arborizations called ‘‘protoglomeruli,’’ and the glial cells begin to migrate to surround
them. Dendrites of the medial cluster projection neurons begin to extend into the forming glomeruli. D, E: During stages 6 and 7, ORN axons
continue to arrive, projection neurons and now local interneurons extend their dendrites into the glomeruli, and glial cells continue to migrate to
surround the glomeruli. F: By stage 9 the antennal lobe architecture is established. G: A single adult glomerulus. ORN axons traveling in the nerve
layer (nl) turn sharply to innervate the apical half of a glomerulus in the glomerular layer (gl). ln and pn dendrites cross the basal border of the
glomerulus, arborize, and form synaptic contacts with ORNs and each other mainly in the basal two-thirds of the glomerular neuropil. Glial cells of the
simple type (75–100/glomerulus) form a sheath around the glomerulus (the processes of several are shown), while complex glial cells (,10/
glomerulus) extend processes into the glomerular neuropil, arborizing in the most apical and in the basal portion of the glomerulus [137].
doi:10.1371/journal.pone.0007222.g001
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weaker labeling for the 30235% interface and the 40+60%
fraction (not shown). Thus it appears that the distribution of these
molecules in various membrane subdomains differs with brain
region, and that the TM proteins studied here are capable of
moving between membrane subdomains. As for the ALs, brain
GPI-Fas II was found in the 25% fraction and the 30235%
interface as expected.
Sequestration of membrane sterols in vitro and in vivo
Methyl-b-cyclodextrin (MbCD) is a water-soluble, seven-
membered ring of amylose molecules that forms complexes with
sterols, which are a major component of all membrane rafts [19].
It has been used to extract sterols from the membranes of cells
growing in culture as a way to study the cellular effect of disrupting
membrane rafts [32,33,77–79]. ORN explants treated with
MbCD displayed a dose-dependent decrease in the patchy
Figure 2. Glycosphingolipids and detergent-resistant patches on ORN axons. A: Explants of antennal olfactory epithelium labeled for
glycosphingolipids (GSLs) using the lectin wheat germ agglutinin (WGA). Patchy labeling suggests that GSLs are confined to membrane subdomains. B:
Higher magnification of axons and growth cones of another 24-hour culture. Patches of WGA labeling extends into growth cone filopodia. C: Individual
neuronslabeledwithVybrant DiI,whichuniformly labelscellmembranes.C9:Neurons re-imagedaftertreatmentwith0.5%TritonX-100at4uCtoextract
the dye from phospholipid membranes but not from detergent-resistant membranes show patchy labeling indicative of membrane rafts.
doi:10.1371/journal.pone.0007222.g002
Figure 3. WGA colocalizes with Triton-resistant Vybrant DiI. A: Explants of antennal sensory epithelium. Vybrant DiI (red) and WGA-Alexa 633
(green). B: Re-imaging after treatment with 0.5% Triton at 4uC shows WGA labeling only where Triton-resistant Vybrant DiI remains. C: Higher
magnification reveals a population of Triton-resistant Vybrant DiI-labeled patches with no detectable WGA labeling.
doi:10.1371/journal.pone.0007222.g003
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known to disrupt membrane rafts by sequestering sterols also
disrupts concentration of GSLs in patches. The persistence of
WGA labeling in cell bodies (Fig. 6C) may indicate that GSLs are
synthesized but not transported to the axons.
Studies using MbCD in vitro have provided useful insights, but
until now no one has used MbCD to study effects in vivo. M sexta
provides a tractable system in which to use MbCD to investigate
the effects of disruption of raft-dependent signaling on develop-
ment in vivo, where axons are navigating through their normal
three-dimensional environment. Unlike most animals and plants,
insects are unable to synthesize sterols de novo and must obtain
them in their diet [80]. Because we injected animals during their
pupal (and therefore non-feeding) phase, we expected that once
sterols were extracted from membranes by MbCD they could not
be replenished by de novo synthesis.
To test for the ability of MbCD to disrupt membrane rafts in
vivo, we took advantage of the fact that GSLs are preferentially
concentrated in these domains and that previous work had shown
that WGA labels GSLs (rather than glycoproteins) on ORN axons
in a developmentally regulated manner [40]. In that previous
study, when no detergent was included in the labeling protocol,
most, if not all, ORN axons of male and female brains were
labeled with WGA along their lengths at stage 7, but in males, by
adulthood, the label appeared only on the axons targeting the
male-specific macroglomerular complex. In the current experi-
ment, seven males at early stage 3 (prior to the arrival of ORN
axons at the AL) were injected with 5 or 7.5 mg MbCD in insect
saline and three were injected with the saline vehicle only. Animals
were allowed to develop to stage 14 (when glomerular architecture
has been well established and ORN axon ingrowth is complete;
n=3) or to stage18 (mature; n=4). Brains were fixed, sectioned
and labeled with WGA. Vehicle-injected control animals (stage-18
animals; n=3) (Fig. 7A) exhibited the characteristic bright labeling
of axons targeting the macroglomerular complex. In contrast,
MbCD-treated animals (Fig. 7B–D) exhibited a dose-dependent
Figure 4. Co-localization of WGA-labeled patches and various signaling molecules expressed by ORN axons. 24 hrs in vitro. ORN axons
extend from explants outside of the field of view. A: Co-labeling with WGA-rhodamine (red) and an anti-EGFR antibody (sc-15827, green): EGFRs are
localized exclusively to WGA-labeled domains. B: Co-labeling with WGA-rhodamine (red) and an anti-neuroglian (Nrg) antibody (3B11, green):
neuroglian molecules exist both in and out of WGA-labeled patches. C: Co-labeling with WGA-rhodamine (red) and an anti-MFas II antibody (C3,
green): most MFas II molecules are located outside of WGA-labeled patches. Arrowheads show regions of co-localization.
doi:10.1371/journal.pone.0007222.g004
Figure 5. EGFR and IgCAM localization probed by sucrose
gradient flotation of detergent resistant membranes. ALs were
separated from brains and homogenized separately. Detergent-resistant
and detergent-soluble membranes were separated by sucrose step-
gradient flotation. Detergent resistant membranes were found in the
25% sucrose layer and at the 30235% sucrose interface, while detergent
soluble membranes were found in the 40 and 60% sucrose layers.
Associated proteins were separated via PAGE and transferred to a PVDF
membrane for immunoblotting. Using an antibody to activated EGFR,
dimers (250 kDa) were found mostly in a detergent-resistant fraction at
the 30235% sucrose interface, smaller amounts were found in the 25%
and 40+60% sucrose layers. For blots probed with an antibody to M sexta
neuroglian,onlythe30235%sucroseinterfacefractionproducedaband.
As for the pEGFR blot, the TM-Fas II blot produced bands for all three
fractions, with the 30235% interface labeled more intensely than the
other two fractions. An antibody to GPI-linked Fasciclin II, expected to be
raft-associated by virtue of its GPI anchor, labeled only the 25% sucrose
and the 30-35% sucrose interface fractions.
doi:10.1371/journal.pone.0007222.g005
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indicating that the GSL-rich membrane subdomains on ORN
axons had been disrupted by treatment with MbCD in vivo, as was
seen in ORNs treated with MbCD in vitro (Fig. 6). Treated animals
exhibited no visually obvious indication of cytotoxicity, such as
significant reduction in antennal nerve diameter [67; see below] or
in the number of neuronal cell bodies associated with the AL.
MbCD treatment also disrupted the general structure of the AL.
The ALs in treated animals often were elongated (Fig. 7B–D) and
displaced laterally relative to their normal positions on the anterior
surface of the protocerebrum flanking the midline. The glomerular
organization of the ALs also was abnormal (Fig. 7B–D). This
disruption was especially obvious when the AL neuropil was
labeled with the lectin Jacalin, which binds to dendrites of AL
neurons, most intensely in the basal regions of glomeruli [40].
Jacalin labeling of control male ALs (Fig. 7A9) reveals the typical
pattern of organization in which the ordinary glomeruli form a
layer surrounding a central coarse neuropil; the male-specific
macroglomerular complex is located in the lateral region of the
lobe near the entry site for the antennal nerve. In contrast, Jacalin
labeling in MbCD-treated animals revealed a dose-dependent
reduction in labeling intensity and a disorganized pattern of small,
oddly shaped glomerulus-like structures (Fig. 7B9–D9); in some
cases, they were located throughout the AL neuropil instead of in a
defined glomerular layer (Fig. 7B9, inset). We could not identify
particular ordinary glomeruli that normally are recognizable by
their shapes and positions [81–83]. The macroglomerular complex
also was smaller and more fragmented, lacking its typical lobular
structure and the distinction among the three compartments that
normally comprise it (Fig. 7B–D, B9–D9).
The pattern seen after MbCD treatment is clearly different from
that seen when the developing AL is deprived of ORN axons
[44,66,84]. In unafferented ALs, glomeruli are absent and the
dendrites of AL neurons arborize in a diffuse layer around a coarse
central neuropil (inset, Fig. 7A9). In the MbCD-treated animals,
the antennal nerves were somewhat smaller in diameter than is
normal (Fig. 7B–D). We considered whether this decrease, likely to
reflect a diminution of the number of ORN axons reaching the
AL, might be responsible for the altered neuropil structure in the
MbCD-treated animals. In a previous study, we removed differing
amounts of the antenna, to determine how many ORN axons are
necessary for normal development of the glomerular array in the
AL. We found that a slender nerve containing axons from only the
proximal 21 antennal annuli (out of 70–80 total), comprising
Figure 6. MbCD treatment alters the distribution of GSL-rich membrane subdomains. Control and MbCD-treated 30-hr ORN explant
cultures were fixed and labeled with WGA (white in A–C; green in A9–C9) and an antibody to horseradish peroxidase (magenta in A9–C9) as a general
neuronal marker. A, A9: As in previous figures, WGA labels small patches on axons in controls. Flattened growth cones exhibit very small patches
(arrowhead in bottom right panel in A9). B: At 1 mM MbCD, there is a marked reduction in WGA labeling of axons. B9: Flattened growth cones exhibit
larger WGA labeled patches (arrowheads), suggesting an aggregation of GSL-rich subdomains as sterols are removed. C, C9: At 2 mM MbCD, WGA
labeling of axons is almost completely eliminated. C: WGA labeling persists in the cell bodies (bright labeling is edge of explant).
doi:10.1371/journal.pone.0007222.g006
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the AL, is sufficient to cause formation of the normal number of
glomeruli, in a normal-appearing array [67]. Therefore, the
diminution in diameter of the nerves seen in the MbCD-treated
animals is not likely to be the cause of the abnormal neuropil
architecture.
Thus, MbCD treatment resulted in loss of WGA-labeling,
which we interpret to indicate the loss or dispersal of GSLs, and in
abnormal AL architecture that could not be attributed simply to
failure of axon ingrowth. An effect of MbCD mediated via
projection neurons also seems unlikely, as previous experiments
have shown that removal of 200 of the total 300 AL projection
neurons, which leaves the dorsal glomeruli without projection
neuron dendrites, does not affect the formation or stability of these
glomeruli [85].
Effect of MbCD treatment on EGFR and Ig-CAM
immunolabeling
M sexta fasciclin II. M sexta fasciclin II (MFas II) is a
homolog of vertebrate NCAM/RnCAM/OCAM [86,87] and acts
primarily as a homophilic adhesion molecule important in
regulation of fasciculation as well as in synapse stabilization and
plasticity [88–92] and neurite outgrowth [93]. In M sexta, Fas II
exists in two forms, transmembrane and GPI-linked [55]. Studies
have shown that TM-Fas II is expressed by a subset of ORN axons
that targets a stereotyped array of 14–21 olfactory glomeruli [10].
The MFas II-expressing axons, which are diffusely scattered across
the width of the antennal nerve as it leaves the antenna, assemble
into large MFas II-positive bundles as they traverse the sorting
zone. MbCD-treated (n=27) and control (n=12) female animals
were allowed to develop to stage 6 so that we could analyze the
behavior of ORN axons as they extended through the SZ and
formed glomeruli. Because an M sexta AL is innervated by
approximately 300,000 very small diameter ORN axons (,0.1–
0.3 mm) [94], use of general axon markers or lipophilic dyes would
not have distinguished individual axons (as they can in Drosophila)
and therefore would not have been useful (see EGFR and
neuroglian labeling, below, for examples of general axon markers).
As a practical alternative, a subset of axons was labeled using
MFas II (C3) immunoreactivity. This approach allowed
visualization of axonal outgrowth, trajectories, and fasciculation
in the olfactory pathway, as well as assessment of possible effects
on the expression of MFas II itself.
In MbCD-treated animals, MFas II labeling was markedly
reduced compared to controls (Fig. 8A, B). After viewing
preparations at normal gain, we examined them again at higher
gain to reveal weak MFas II labeling, so that we could assess the
trajectories of MFas II-positive axons (Fig. 8C, D: 5 mg dose;
Fig. 8E, F: 7.5 mg dose). These axons showed roughly typical
behavior in the SZ, such as changing trajectory and forming MFas
II-positive bundles as they exited the SZ, but many axons traveled
either alone or in bundles far smaller and less discrete than usual
(Fig. 8D–F). Within the AL, MFas II-positive axons normally
target 14–21 glomeruli [10]. For the ALs of MbCD-treated
animals shown in Figure 8, there were 13 and 18 MFas II-positive
glomerulus-like axon terminations present at the 5-mg dose and 11
and 15 MFas II-positive terminations at the 7.5-mg dose, thus
approaching or within the normal range. The MFas II-positive
axon terminations in the treated ALs lacked the spheroidal shape
of the typical developing glomerulus at this stage. Also, the borders
of the glomerulus-like structures in treated ALs were less well
defined; at higher magnification, many MFas II-positive axons
were found to extend aberrantly from the sides of their glomeruli
(Fig. 8F), a pattern normally seen only early in protoglomerulus
Figure 7. MbCD causes abnormal antennal lobe development.
MbCDinjectionatearlystage3,animalsallowedtodeveloptostage14(A–
C) or 18 (D). Midline totheleft. Brains were double labeled withWGA (A–D)
and with Jacalin (A9–D9 plus insets). A: Control – ORN axons terminatingin
the male-specific macroglomerular complex (MGC, consisting of the
Cumulus(C) and Toroids 1 & 2 (T1&T2))label with WGA; axons terminating
in the ordinary glomeruli (*) do not. A9: Jacalin-labeled AL neuron
dendrites arborize in a glomerular pattern in both ordinary and MGC
glomeruli. (CNP): coarse neuropil. A9 (inset): AL neuron dendrites in an
untreated AL chronically deprived of ORN axon innervation have a diffuse,
aglomerular arbor. B: 5m gM bCD. Male-specific ORN axons retain some
WGA labeling, but both MGC and ordinary glomerulus organization is
perturbed and lobes elongate. Bright WGA labeling of the lateral and
medial cell body clusters (LC, MC) is due to high WGA affinity for a nuclear
membrane protein [40]. B9: Jacalin labeling highlights the disordered
arrangement and lower number of glomeruli in treated animals. B9
(inset): In another animal injected with 5 mg MbCD, glomerulus-like
structures appear even in the normally glomerulus-free coarse neuropil.
C,D: 7.5 mg MbCD. Bright WGA labeling of MGC axons is completely lost
though an MGC-like structure (MGC*) is present in panel C. C9,D9: Lobular
structure of neuropil is faintly visible (arrowheads), but organization of the
lobe is deeply perturbed despite the presence of substantial antennal
nerves (AN). OT: output tracts. SZ: sorting zone region of the AN. Scale bar
in A applies to all panels.
doi:10.1371/journal.pone.0007222.g007
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7222Figure 8. MbCD treatment dramatically reduces labeling for MFas II and perturbs the organization of MFas II-positive glomeruli. A:
Control AL from a stage-6 animal labeled with anti-MFas II (C3). ORN axons undergo dramatic changes in fasciculation and trajectory as they traverse
the sorting zone (SZ); MFas II-positive and -negative axons segregate into relatively large distinct fascicles as they exit the SZ. A9: The same section
labeled with the nucleic acid dye Syto 13 to show cell nuclei. Neuropil glial-cell processes extend partially around developing glomeruli and some
glial cell bodies migrate into the neuropil between glomeruli (arrowheads). MC and LC: medial and lateral clusters of AL neuron cell bodies. B: 5m g
MbCD. With collection parameters identical to those used in panel A, a stage-6 AL displays almost no visible MFas II labeling (brightest glomeruli are
indicated by arrows). B9,C 9: Neuropil glial migration is somewhat reduced. C–F: Increased gain settings for the MFas II channel to visualize axon
behavior. C: MFas II-positive axons in same AL shown in panel B show changes in trajectory and fasciculation that typically occur in the SZ, but then
form glomeruli more variably sized than in controls. The large Fas II-positive, tightly fasciculated bundles normally present as the axons exit the SZ are
absent and the axons traveling in the nerve layer are less tightly bundled. D, D9: 5m gM bCD. Glomeruli from another animal are also smaller in size.
Neuropil glial cells show minimal migration, but SZ glial cells have migrated into the antennal nerve (AN). E,E9,F,F9: 7.5 mg MbCD. Methanol/formalin
fixation, no Triton permeabilization. Gain settings for E and F were increased as in C and D to permit visualization of residual Fas II labeling. Glomeruli
are small and irregularly shaped. Numerous axons extended laterally and centrally past the main body of the Fas II-positive glomerulus-like structures.
Few NP glial cells migrated while SZ glial cells displayed robust migration.
doi:10.1371/journal.pone.0007222.g008
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glomerulus-like structures into the central coarse neuropil of the
AL, which they also would not do normally (Fig. 8E, F).
Preparations were routinely double-labeled with the nucleic acid
stain Syto 13 to visualize the pattern of glial nuclei in the SZ and
around glomeruli (n=64). SZ glia appeared to have migrated
normally in MbCD-treated animals. In contrast, at both the 5 and
7.5-mg doses, very few neuropil glial cells had migrated to
surround glomeruli (Fig. 8D9–F9).
Because of the irregular size and shape of glomeruli, the lack of
a glial-cell surround, and the disrupted organization of the
glomerular array in treated animals, we were unable to determine
whether the glomeruli were in their correct positions within the
ALs, and thus whether the MFas II-positive axons had targeted the
correct positions. As in the animals examined at stages 14 or 18
(Fig. 7), antennal nerves were somewhat smaller in diameter, but
we did not see overt signs of cytotoxicity, such as a reduction in the
number of glial cells or AL neurons.
While MFas II labeling in vivo showed marked reduction in
labeling intensity in the antennal nerve and in the AL, it was
important to also examine the effect of MbCD treatment in vitro,
which would reduce the impact of competing signals present in the
normal 3D environment and which would allow clearer resolution
of axons and growth cones. Our analysis of labeling was qualitative
because the proportion of labeled axons in each explant varied and
fasciculation of small groups of axons, a varying proportion of
which were MFas II-positive, precluded quantification. Instead we
systematically imaged each field in which there were labeled axons
present at a density at which individual axons, small bundles of
axons, and isolated growth cones could be resolved.
The set of images from control, and 1 and 2 mM MbCD dishes
were compared. In control conditions, labeling for MFas II showed
that a portion of the axons were MFas II-positive (Fig. 9A1–4), some
strongly and some moderately, mirroring the in vivo staining pattern
[10]. 24-hr exposure to MbCD visibly reduced labeling intensity.
Strongly labeled MFas II axons were rare; most of the labeled axons
were now only weakly labeled in the 2-mM dishes (Fig. 9C1–4). An
intermediate patternwasvisible in the 1-mM dishes(Fig. 9B1–4). We
did not see major differences in the range of growth cone
morphologies in the presence of MbCD, but did see reduced
axonal length at the 2-mM dose.
Neuroglian. Neuroglian, an insect homolog of the vertebrate
L1 [96,97], is expressed in M sexta by both ORNs and glial cells [4;
Oland, unpublished]. Neuroglian is present along the length of the
ORN axons during most of the period of axon ingrowth, but is
stabilized against extraction by detergent only in the SZ [4].
Because the in vitro co-localization experiments described earlier
suggested that neuroglian could be found both in and outside of
WGA-defined membrane domains,we labeled the brains of MbCD-
treated and vehicle-injected control animals to determine the effect
of MbCD on the disposition of neuroglian. We had found previously
that the pattern of neuroglian labeling is dependent on the type of
fixation/permeabilization used [4]. In the brains of control animals
fixed with paraformaldehyde and permeabilized with Triton, an
antibody against neuroglian labels ORN axons and glial cells in the
SZ, axonal terminal branches in developing glomeruli, and glial
processes surrounding glomeruli (Fig. 10A). In control brains fixed in
methanol/formalin, which rapidly precipitates and fixes proteins in
place, ORN axons also are labeled in the antennal nerve distal to the
SZ (Fig. 10B), as they are in paraformaldehyde-fixed brains not
permeabilized with Triton (not shown).
Note that the similarities in neuroglian labeling following two
different fixation/permeabilization protocols (paraformaldehyde
without Triton, and methanol/formalin) but not with paraformal-
dehyde + Triton, argues against an unmasking of epitopes distal to
the SZ [4]. We have interpreted these differences in labeling with
different protocols to mean that neuroglian molecules exist in two
states along the axons of normal animals: a Triton-resistant state in
the SZ and a Triton-extractable state distal to the SZ; the difference
may be attributed to axon-glia interactions in the SZ that result in
neuroglian stabilization via homophilic binding between cells and
subsequent anchoring of the molecules to the cytoskeleton [4], as
has been demonstrated for both L1 and neuroglian [98–102].
Because the relative contributions to resistance to Triton extraction
made by homophilic binding and by anchoring to the cytoskeleton
are not clear in Manduca, however, we use the word ‘‘stabilization’’
to encompass both of these possibilities.
When paraformaldehyde-fixed, Triton-permeabilized brains
from MbCD-treated animals were examined, neuroglian was not
detectable, indicating either that it was not present or that it had
not been stabilized against Triton extraction during histological
preparation, even in the SZ (Fig. 10C, n=3). In methanol/
formalin fixed tissue, however, neuroglian immunocytochemistry
after MbCD treatment revealed labeling of ORN axons and of the
glial cells that surround glomeruli (Fig. 10D, n=3). Thus in
MbCD-treated animals, neuroglian present on axons traversing
the SZ does not become stabilized as it does in untreated animals,
suggesting that neuroglian stabilization is linked to the existence of
sterol-rich gMSDs.
As mentioned above [and see 4], neuropil glia also express
neuroglian resistant to Triton extraction as they migrate to
surround protoglomeruli. Brains of MbCD-treated animals
processed using paraformaldehyde fixation/Triton permeabiliza-
tion displayed no labeling for neuroglian (Fig. 10C), yet methanol/
formalin fixation and neuroglian immunocytochemistry of
MbCD-treated animals revealed that neuropil glia continued to
express neuroglian and, though unable to migrate normally to
surround protoglomeruli, were nevertheless able to extend their
processes around developing glomeruli (Fig. 10D, arrows),
suggesting that treatments designed to disrupt sterol-rich mem-
brane subdomains disrupts signaling underlying cell migration but
not process extension in one class of glial cells.
Unlike the case for MFas II, neuroglian labeling is present on all
axons in cultured ORNs, with the labeling generally quite uniform
along the axon, as we find for ORN axons in vivo when not extracted
with Triton. After treatment with 1 mM MbCD, there was a small
but consistent decrease in labeling intensity (Fig. 11B1–3) in most
axons, while those treated at the 2 mM level displayed a greater
decrease(Fig.11C1–3).A subset ofthe axonswerestronglylabeled in
all cases, including the controls, but in the treated dishes, the
incidence of strongly labeled axons decreased; at 2 mM, strongly
labeled axons were rare (Fig. 11C1).
EGF Receptors. EGFRs are known to have a variety of
developmental roles in vertebrates and invertebrates [103,104]. In
the moth olfactory pathway, EGFRs are expressed along the
lengths of ORN axons throughout their extent, but are
phosphorylated - a measure of activation [56] - in the sorting
zone and in glomeruli as they become stable structures [4]. Since
our in vitro results indicated that the EGFRs are localized to
gMSDs, we tested whether disrupting the integrity of gMSDs with
MbCD would disrupt EGFR signaling.
Using an antibody to the EGFR that recognizes both the
unphosphorylated and the phosphorylated forms, we found
EGFRs to be present along the length of the ORN axons of
MbCD-treated animals (n=4), including in the SZ, just as they are
in saline-injected controls (n=2) (Fig. 12A, B). When we used an
antibody that recognizes only the phosphorylated EGFR,
however, we found the typical SZ and glomerular labeling of
Membrane Lipid Domains
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labeling in ORNs of MbCD-treated animals (n=22) (Fig. 12C, D).
Thus EGFRs are present, but do not appear to be activated in
MbCD-treated animals.
MbCD would be expected to disrupt gMSDs on all cell types,
and the function of any signaling molecule whose competence
depends on association with these domains would have been
compromised, not just the EGFRs and the IgCAMs addressed
here. To help us understand whether MbCD blocks neuroglian
stabilization by preventing EGFR activation, we took advantage of
the facts that we had found previously that blocking EGFR
activation with the specific inhibitor PD168393 [62] leads to loss of
neuroglian labeling [4], and that several studies have linked
homophilic binding of neuroglian/L1 molecules with EGFR
activation and subsequent binding of neuroglian/L1 to the
cytoskeleton [100,105,106]. Using the technique of alternate
Figure 9. MbCD treatment of cultured ORNs decreases MFas II labeling. A1–4: In control conditions, a subset of ORN axons extending from
explants are MFas II-positive, some strongly (arrowheads), some moderately (open arrowheads). Arrows indicate several unlabeled axons visible
under brightfield optics. B1–4: After 24-hr exposure to 1mM MbCD, more MFas II axons are moderately or only weakly labeled. C1–4: At 2 mM MbCD,
nearly all MFas II-positive axons are only faintly labeled. Rare axons that appear brightly labeled (C3) were always less strongly labeled than those
found in control or 1 mM dishes. No consistent changes were seen in axonal or growth cone morphology at the 1 mM dose; axon outgrowth was
reduced at the 2 mg/ml dose.
doi:10.1371/journal.pone.0007222.g009
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EGFR activation alone, without disrupting membrane subdo-
mains, could lead to loss of neuroglian stabilization, as opposed to
loss of expression. Animals were treated with PD168393 at early
stage 5 to block EGFR activation starting 2–3 days prior to stage
7, when Triton-resistant neuroglian labeling in the SZ is normally
at a maximum. We compared DMSO-injected control animals
(n=4) and DMSO + PD168393-injected animals (n=7), using
both standard (4% paraformaldehyde with Triton permeabiliza-
tion) and alternative (methanol/formalin, without Triton) fixation
procedures for neuroglian.
Standard immunocytochemistry of control brains (n=2)
produced the typical pattern of strong neuroglian labeling only
in the SZ and in glomeruli (Fig. 13A), while treated brains (n=3)
displayed significantly reduced labeling, especially in the SZ
(Fig. 13B). The neuroglian labeling that was visible in the treated
animals examined at stage 7 was similar to that seen in untreated
animals at stage 6 [4], suggesting that neuroglian that already had
been stabilized at the time of blockade of EGFR activation
remained so. In contrast, methanol/formalin fixation/permeabi-
lization resulted in very similar levels of labeling for neuroglian in
control (n=2) and treated (n=4) animals, (Fig. 13C, D),
suggesting that neuroglian was present, but not stabilized, in
ALs in which EGFR activation was blocked with PD168393. This
evidence that prevention of EGFR activation also prevents
neuroglian stabilization in the SZ suggests that MbCD’s effect
on neuroglian stabilization could, indeed, be an indirect effect via
its effect on EGFR activation.
As was the case for WGA, ORN explants treated with MbCD
and labeled with an antibody to the EGFR exhibited a dose-
dependant decrease in punctuate labeling of axons and growth
cones (Fig. 14). At the 0.5 mM dose, axons, growth cones, and
filopodia exhibited no change in labeling compared to controls
(Fig. 14A1–2,B 1–2). Explants treated with 1 mM MbCD displayed
a decrease in axonal and filopodial labeling in some, but not all,
ORNs (Fig. 14C1–2). Labeling of growth cones was not changed.
At the 1.5 mM MbCD dose, however, all ORNs showed a
significant decrease in labeling for the EGFR in axons, growth
cones and filopodia (Fig. 14D1–2). The loss of punctuate EGFR
labeling was not accompanied by a detectable increase in diffuse
EGFR labeling. This result could be due either to loss of EGFRs
or to an inability to detect EGFRs when they are not clustered.
However, as shown above, EGFRs were detectable by immuno-
cytochemistry after in vivo treatment, presumably because the
signal from the hundreds of very fine ORN axons in a single
optical section adds to reveal the EGFR label. It therefore appears
Figure 10. MbCD treatment decreases neuroglian stabilization. A,B: ALs of untreated brains show neuroglian labeling under two fixation
paradigms. A: Standard paraformaldehyde fixation and Triton permeabilization produces labeling of ORN axons only in the SZ, the AL nerve layer and
the glomerular layer, but not in the distal AN. B: Fixation with methanol/formalin demonstrates that neuroglian is also present distal to the SZ in the
AN. C,D: 5m gM bCD. Collection settings identical to those used in panels A and B, respectively. C: Standard fixation and permeabilization as in A. No
neuroglian labeling is detected. D: Fixation with methanol/formalin. Neuroglian is present in the nerve and NP glial cells, though at lower-than-
normal levels. D also clearly demonstrates that neuropil glial cells, while not migrating to surround glomeruli, did extend processes (arrows).
doi:10.1371/journal.pone.0007222.g010
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rather than removal from, the membrane.
Effect of MbCD treatment on axon targeting
Sequestration of membrane sterols clearly leads to abnormalities
in ORN axon outgrowth, glomerulus formation, and migration of
neuropil glia, and the abnormal patterns of MFas II-positive ORN
axons visualized in MbCD-treated preparations hinted at the
possibility of targeting defects (Fig. 8). To ask directly whether
MbCD-treatment leads to mistargeting of ORN axons, we
examined a set of ORN axons that normally target a single
glomerulus (Fig. 15A,B). These axons label with an antibody to
human Ankyrin B, though western blots of M sexta brains indicate
that the epitope recognized is not a homolog of Ankyrin B (data
not shown). For the purposes here, the precise nature of the
epitope is not important; the antibody is useful here because of the
specificity of labeling for ORN axons that target a unique
glomerulus (we will call it ‘‘glomerulus X’’), from animal to animal.
Glomerulus X is located dorsally and posteriorly, adjacent to
the tract of primary neurites emanating from the medial cluster of
Figure 11. MbCD treatment modestly decreases neuroglian labeling in cultured ORN axons. Under control conditions (A1–3), neuroglian
labeling appears along the length of the axons and in the growth cones, including the filopodia (arrowheads), and most axons were brightly labeled.
After 24-hr exposure to 1 mM MbCD (B1–3), labeling intensity was somewhat reduced but the distribution of labeling along the axon and in growth
cones was unchanged. Exposure to 2 mM MbCD (C1–3) resulted in a further reduction in labeling intensity across the population although some
axons remained brightly labeled (C1).
doi:10.1371/journal.pone.0007222.g011
Membrane Lipid Domains
PLoS ONE | www.plosone.org 15 September 2009 | Volume 4 | Issue 9 | e7222AL neuronal cell bodies. The axons that contribute to the
glomerulus are gathered in the SZ from across the width of the
antennal nerve to form one large fascicle and a few smaller ones
that target the glomerulus (Fig. 15A, B). Double-labeling
experiments in normal ALs using the Ankyrin B antibody and
the MFas II antibody revealed that glomerulus X is consistently
one of the MFas II-negative glomeruli (Fig. 15C).
In animals treated with MbCD and processed for Ankyrin B
immunocytochemistry (n=11), we found glomerulus X to be
present in roughly the correct position (adjacent to the primary
neurite tract of the medial cluster), although it was impossible to
say whether its position was completely normal due to the MbCD-
induced disorganization and elongation of the antennal lobe
(Fig. 15D–F). There was no indication that the axons extended
beyond the boundaries of the target glomerulus either laterally or
medially as was seen in the MFas II-positive glomeruli in treated
animals (Fig. 8E, F); all of the labeled axons terminated in a well-
defined glomerulus.
Discussion
The results presented here show that subdomains in the
membranes of ORN axons in the moth M sexta include the receptor
tyrosine kinase EGFR and the IgCAMs neuroglian and fasciclin II.
MbCD treatments designed to disrupt sterol-rich gMSDs in vivo
result in loss of EGFR activation and of neuroglian stabilization in
the SZ region of the olfactory pathway, and in significant decrease
in fasciclin II expression by ORN axons. MbCD treatment during
the period of ORN axon ingrowth affects not only the spatial
organization of the glomerular array in the AL, but also the
behavior of ORN axons as they grow through the SZ and form
terminal arborizations in the AL. Migration, but not process
extension, by neuropil glia is blocked following MbCD treatment,
while proliferation and migration of SZ glia appears unaffected.
Distribution of EGFRs, IgCAMs and GSL-rich subdomains
in the membranes of ORN axons
In previous work [40], we showed that each of the major cellular
elementsofthe primary olfactory pathway - ORNs, glial cells, andAL
neurons - has a distinctive lectin-binding signature in the developing
and adult animal. In particular, the ORN axons express one or more
glycosphingolipids (GSLs) that are recognized by WGA. Sucrose-
gradient flotation revealed a detergent-resistant membrane fraction
that contained sphingomyelin, an important component of mem-
b r a n er a f t s ,a sw e l la saG P I - a n c h o r e di s o f o r mo fM F a sI It h a tw o u l d
be expected to associate with membrane rafts [63]. In the current
study, we have shown that labels for molecules expected or known to
partition into membrane rafts are often distributed within fixed,
cultured ORN axon membranes in a punctate pattern that is
consistent with a distribution within rafts or platforms.
Figure 12. MbCD treatment blocks activation of EGF receptors. A,B: Labeling with an antibody to the EGF receptor (red) that recognizes the
receptor regardless of activation state. The receptor is present on ORN axons in both control (A) and MbCD-treated (B) animals. Glial cells beginning
to form envelopes (arrowheads) around protoglomeruli in panel A. C,D: Labeling with an antibody to the activated EGF receptor (red) shows labeling
in the SZ and developing glomeruli in controls (C), but not in MbCD-treated animals (D).
doi:10.1371/journal.pone.0007222.g012
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almost always associated with domains that label with WGA, while
sucrose gradient flotation of detergent-resistant membranes,
followed by western blots using an antibody to phosphorylated
EGFRs suggested that EGFRs exist both in and out of these
domains. The apparent discrepancy may be due to the very
function hypothesized for rafts and platforms, that of concentrat-
ing certain molecules in closer proximity than they might be in the
typical lipid bilayer [21,24,25,29]. Thus the lack of detectable
labeling outside of the GSL-rich domains could simply be due to
greater distance between EGFR molecules, resulting in a diffuse,
difficult to detect, labeling pattern. Alternatively, EGFR molecules
in GSL-rich domains might move into phospholipid domains
during the Triton solubilization and sucrose flotation process due
to the lack of a GPI anchor [107]. Similar in vitro colocalization
studies suggested that neuroglian and TM-MFas II are found in
and outside of the WGA-labeled gMSDs, while immunoblots
suggest that they are localized exclusively (neuroglian) or primarily
(TM-Fas II) to Triton-resistant membrane subdomains. In light of
our finding that WGA labels only a subset of Triton-resistant
subdomains visualized with Vybrant DiI, these results suggest that
neuroglian and TM-Fas II are found in multiple gMSDs of varying
composition, only some of which label with WGA. In addition, it is
possible that the localization of these IgCAMs depends on their
homophilic binding in trans or multimerization in cis [37,87,105].
Transmembrane proteins are also known to move in and out of
membrane subdomains based on fluctuations in membrane
elasticity [26,108,109] or movement of other molecules into or
out of those domains (see e.g., [110]).
Disruption of GSL-rich membrane subdomains and
effects on organization of the olfactory pathway
Is there a non-specific effect on ORN axon growth?. The
diminution of WGAlabeling in male-specific adultaxons terminating
in the MGC indicates that the GSL ligands were present in
decreasing amounts after treatment with MbCD and suggests that
gMSDs had been disrupted by sequestration of sterols. A possible
consequence might have been a general effect on process outgrowth
via disruption of interactions between gMSD-associated signaling
molecules and downstream effectors that mediate changes in
Figure 13. Blocking EGFR activation blocks neuroglian stabilization. Control (DMSO) and PD168393-treated animals injected at early stage
5. A: Control – paraformaldehyde fixation and Triton permeabilization. Neuroglian labeling typical of stage-7 olfactory pathway. B: PD168393-treated
animals processed as in A. Much weaker labeling, typical of that normally seen at late stage 5 or early stage 6 [4]. C, D: Fixation/permeabilization by
methanol/formalin results in strong neuroglian labeling in both controls (C) and treated animals (D), thus confirming the presence of neuroglian at
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T h e r ei ss o m ee v i d e n c et h a tM bCD also affects non-raft membrane
domains by extracting sterols there as well; a few studies have
reported that MbCD extracts a significant amount of phospholipids,
though others find little or no extraction [111]. In vivo,w eu s e dd o s e s
(5 and 7.5 mg) estimated to produce circulating MbCD
concentrations of 1.9 and 2.8 mM (extrapolated from Morton and
Truman [112] using an estimated hemolymph volume of 2 ml),
placing them at the low end of the range of doses used in previously
reported cell culture experiments (0.5–20 mM; [111]). At the doses
used here, most ORN axons continued to extend into the AL, the
dendrites of AL neurons sent processes into glomeruli, SZ glia
migrated normally, and neuropil glia extended processes into the
neuropil. Our in vitro doses, 0.5 to 2 mM, reduced outgrowth only at
the 2-mM level. Together these results suggest that the effects of
treatment on the various elements of the olfactory pathway were not
simply non-specific effects on growth due to generalized membrane
disruption.
How does MbCD treatment affect neuron-glia interactions
in the developing olfactory pathway?. Because we are
interested in understanding the role of raft-based signaling as it
affects interactions between ORN axons and between ORN axons
and glial cells, we examined the ORN axons and glial cells in each
region of the olfactory pathway to determine inwhat waydisruption
of membrane subdomains had affected them.
Normal ORN axons behave differently in each region of the
developing olfactory pathway, and each region has a specific
population of glial cells [9,44,113]. In previous studies, we
documented at the cellular level several important interactions
between neurons and glial cells, including: (1) populating the SZ
by ORN-axon induction of proliferation and migration of central
glial cells that lie at the entry to the AL; (2) glia-dependent
regulation of axonal fasciculation in the SZ; (3) ORN axon-
induced activation of neuropil glial-cell migration and process
extension around developing glomeruli; and (4) stabilization of
axonal protoglomeruli by neuropil glial cells [3].
Figure 14. MbCD treatment of cultured ORNs decreases EGFR labeling. Under control conditions (A1–2), punctuate labeling for EGFRs (using
antibody ab49966) appears along the length of the axons and in the growth cones (arrows), including the filopodia (arrowheads). ORNs exposed to
0.5 mM MbCD for 24 hours display no discernable changes in morphology or labeling for EGFRs (B1–2).After 24-hr exposure to 1 mM MbCD (C1–2), the
punctuate labeling of filopodia and axons is reduced but labeling of flattened growth cones remains. Exposure to 1.5 mM MbCD (D1–2) results in nearly
complete absence of labeling of axons and filopodia; weak labeling of some growth cones persists. Scale bar in A1 applies to all panels except D2.
doi:10.1371/journal.pone.0007222.g014
Membrane Lipid Domains
PLoS ONE | www.plosone.org 18 September 2009 | Volume 4 | Issue 9 | e7222MbCD treatment initiated at stage 2 had little, if any, effect on
glial-cell migration into the SZ. MFas II-positive ORN axons
within the SZ, however, displayed significantly reduced fascicula-
tion, especially at the 7.5 mg dose (Fig. 8E, F). The fascicles of
MFas II-positive axons were less robust at both dosages, but
because the MFas II labeling was so diminished, we were unable to
determine if MFas II-positive axons were bundled only with their
normal MFas II-positive partners as they left the SZ.
The organization of the AL neuropil in MbCD-treated animals
was disrupted in several ways that suggest that gMSD-based
Figure 15. MbCD treatment does not prevent correct regional targeting of the axons innervating an identified glomerulus
(glomerulus X). Untreated (A–C) and MbCD-treated (D–F) animals. A,B: Stage 7. An antibody to human ankyrin B (yellow) labels ORN axons
targeting a single glomerulus located dorso-posteriorly close to primary neurites of the medial cluster of AL neurons (outlined with dashed line).
Neuronal cell bodies and glial nuclei labeled with Syto 13 (blue). C: Double labeling with the ankyrin B antibody (magenta) and the MFas II antibody
(green) demonstrates that glomerulus X (arrow) is Fas II-negative. D–F: 7.5 mg MbCD, injected at early stage 3, brain dissected at stage 7. Ank B
axons target a single glomerulus located near the primary neurites of the medial cluster of AL neurons although the shape of the glomerulus is
variable and the pattern of fasciculation in the SZ is somewhat abnormal.
doi:10.1371/journal.pone.0007222.g015
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development of the antennal lobe. First, the organization of the
glomerular array was abnormal. In males, the typical morphology
of the macroglomerular complex was lost and its size decreased. In
animals in which ordinary glomeruli formed, they were oddly
shaped, and distributed abnormally within the neuropil.
Second, the cell bodies of neuropil glia failed to migrate toward
the center of the neuropil to surround and stabilize protoglomeruli
[67], though they did extend processes. Glial cell process extension
and migration normally is induced by the arrival of ORN axons
[44]. The possibility exists that their failure to migrate in treated
animals is the result of disruption of upstream processes critical to
normal development, but the extension of neuropil glial processes,
a requisite precursor to migration, suggests that initial signaling
between glia and ORN axon terminals occurred normally. Thus it
seems likely that the effects of MbCD treatment were on internal
mechanisms by which migration of the glial cell body is coupled to
process extension [e.g., 114].
In earlier studies we saw that glial processes alone can maintain
glomerular structure into adulthood [1]. On the other hand, the
failure to restrict the terminal branches of some axons (e.g., MFas
II-positive axons, Fig. 8E–F) to their glomerular territory may
reflect either less robust glial envelopes around each glomerulus or
loss of gMSD-based signaling between glial processes and ORN
growth cones that restricts axon terminal branches from crossing
the glial borders between glomeruli. We found that the MFas II-
positive axons displayed aberrant projections extending across
glomerular borders while the axons targeting the MFas II-negative
‘‘glomerulus X’’ in MbCD-treated animals did not. This finding
suggests that subsets of axons differentially weight the signals
presented by the glia forming glomerular borders and by the axons
with whom they traveled to their target.
Third, the dendrites of normal AL neurons have characteris-
tically glomerular arbors. In the MbCD-treated animals, however,
AL neurons exhibited a dendritic phenotype intermediate between
the normal glomerular morphology and the diffuse, aglomerular
arbors typical of AL neurons developing in ALs in the absence of
ORNs ([44,65,84]; reflected in Fig. 7). As was the case for the
ORN axons, the abnormal morphology of the AL dendrites could
be a consequence of the loss of a robust glial envelope around
developing glomeruli, itself possibly a consequence of loss of
gMSD-based signaling interactions directly between ORN axons
and AL neuron dendrites. It cannot be due to an insufficient
number of ORN axons to induce glomerulus formation, however,
because we previously showed that over 30% of ORN axons must
be removed before glomerulus number is decreased, while greater
reductions, up to 88%, will decrease the number of glomeruli but
not the distribution of the glomeruli within the neuropil. Only at
more than 88% reduction do we see loss of glomerular
organization [67].
Taken as a whole, our results suggest that gMSD-based signaling
may be critical to normal development of the AL via effects on
neuron-neuron and/or neuron-glia signaling, some of which are
likely to be the consequence of loss of EGFR-based signaling.
Importantly, our results also suggest that several of the cellular
changes that occur as the olfactory pathway develops do not
depend on gMSD-based interactions, regardless of the underlying
molecular players. These include extension of neuropil glial-cell
processes around developing glomeruli and migration of SZ glia
into the entry region of the antennal nerve to populate the SZ.
Our limited assessment of the accuracy of ORN targeting, using
labeling of male-specific axons and the axons targeting glomerulus
X, indicated that ORNs targeted approximately the correct region
of the AL. Their ability to do so suggests that at least some ORN
axons do not depend on gMSD-based signals to navigate to the
correct region of the lobe.
Disruption of membrane subdomains and effects on
EGFR and the IgCAMS neuroglian and fasciclin II
To what extent did membrane subdomain disruption
specifically affect expression and function of the IgCAMs
and the RTKs?. To better understand the relationship between
gMSDs and both the IgCAMs and the EGFR, we wanted to
determine whether a molecular interaction between the CAMs and
the EGFR initiates signaling cascades that underlie the axonal and
glial interactions that drive ORN axonal navigation and sorting, and
glomerulus formation and stabilization. Vertebrate EGFRs are
activated by a wide range of ligands (EGF, TGF-a, heparin-
binding EGF, betacellulin, amphiregulin, epiregulin, epigen and
neuregulins; [115]). Insects appear to lack an EGFand rely instead on
a number of TGF-a and neuregulin homologs (spitz, vein, etc.) for
ligand-mediated activation of the EGFRs [103]. Growing evidence in
insects suggests that RTK activation also can be mediated by
homophilic IgCAM interactions in cis and in trans [93,105,116,117].
Activation of these receptors in turn affects stabilization of the
IgCAMs within the membrane [4,101,106]. Previous experiments in
other systems in which EGFR activation, or fasciclin II or neuroglian
expression was specifically blocked pharmacologically or by genetic
manipulation have revealed axon stalling and abnormal fasciculation
phenotypes [86,116,118,119]. Similarly, blocking EGFR activation
in Ms e x t aleads to fasciculation defects and axon stalling in the SZ, as
well as to loss of neuroglian stabilization ([4; present study], thus also
supporting a functional link between EGFR activation and
neuroglian binding and stabilization. If, as the current study
suggests, the molecular interaction occurs in association with a
membrane subdomain, we can expect to find that activation of the
EGFR induces activity in molecular partners also associated with
such a subdomain.
The current study contributes three important pieces of
information supporting a link between EGFR function, neuroglian
stabilization, and an involvement of membrane subdomains in
EGFR and neuroglian function and fasciclin II expression or
transport.
First, activation of EGFRs on ORN axons of M sexta, which
normally occurs only in the SZ and in developing glomeruli [4],
appears to require intact, sterol-rich membrane subdomains. Our in
vitro results indicate that the presence of visible clusters of EGFRs in
ORN axons is reduced after disruption of membrane subdomains
while our in vivo results indicate that EGFRs are present, but not
activated, following disruption of subdomains with MbCD.
It is important to stress, however, that our results should not be
interpreted to suggest a widescale blockade of EGFR activation, as
would be expected for PD168393 treatment. We would expect
that the EGFR activation throughout the brain that is important
for cell differentiation, migration, and survival [103] would still be
accomplished via the traditional ligand-mediated avenues (TGFa
and neuregulin families), and that it is the ligand-independent
activation pathway, caused by multimerization of IgCAMs
binding in trans and in cis [105], that was affected. This would
explain the absence of detectable cell death and the phenotypes of
perturbed axon fasciculation and loss of NP glial migration,
processes which would require functional coupling of membrane-
bound IgCAMs to the cytoskeleton.
Second, labeling for detergent-resistant neuroglian, which
normally is found in ORN axons only from their entry into the
SZ until they penetrate the neuropil glial cell layer to form
protoglomeruli [4], was eliminated in MbCD-treated animals
although neuroglian remained present along ORN axons, as
Membrane Lipid Domains
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with MbCD, which allowed examination of labeling in individual
axons, showed there to be a visually obvious but relatively small
decrease in labeling intensity across the population of ORN axons.
Based on the combination of in vivo and in vitro results, the latter
similar to those seen for L1 in cultured hippocampal neurons
treated with the raft-disrupting agent fumonisin B1 [120], we
conclude that disruption of membrane subdomains reduces but
does not prevent trafficking of neuroglian along the ORN axons,
but does eliminate stabilization of neuroglian in the SZ [4].
Third, in M sexta treated with PD168393, which irreversibly
inactivates the kinase function of the EGFR, but not other protein
kinases ([62]), Triton-resistant neuroglian labeling of ORN axons
is virtually eliminated, though alternate fixation/permeabilization
processing shows neuroglian to be present at normal levels [4;
current study]. These results suggest that EGFR activation is
essential for neuroglian stabilization and are consistent with the
results of Sepp and Auld [119], who reported that expression of a
dominant-negative EGFR (kinase dead) in Drosophila decreased
‘‘expression’’ of neuroglian by glial cells (as determined by
immunocytochemistry using Tween 20).
Our current results indicate that neuroglian exists both in and
out of WGA-labelled gMSDs (explant cultures), but exists only in
Triton-resistant fractions (sucrose gradient-western blots), and thus
must also exist in gMSDs that do not label with WGA (see also
[40]). Together these results suggest that interactions between
neuroglian and the EGFR could depend in part on regulating
neuroglian partitioning between the EGFR-containing gMSDs
that label with WGA and gMSDs that do not label with WGA and
do not contain EGFRs.
Additional experiments will be needed to determine the extent
to which the absence of neuroglian stabilization following MbCD
treatment is due to a) perturbation of homophilic neuroglian
binding in cis and trans (previously shown to activate EGFRs;
[105,116]), b) loss of activation of a component of the EGFR to
MAP kinase signaling pathway (shown to lead to attachment of L1
to the cytoskeleton; [100,106]) or c) perturbation of neuroglian’s
ability to link to the cytoskeleton by recruiting or binding to
molecules such as ankyrin, doublecortin, or members of the ezrin-
radixin-moesin family [100,105,106,121–132]. Nevertheless, the
current experiments suggest that gMSDs are essential for ligand-
independent EGFR activation and for anchoring of neuroglian to
the cytoskeleton, both required for normal extension and sorting of
ORN axons.
In contrast to our results for neuroglian, in which MbCD
treatment altered the stabilization of the moleculesand produced
only a small decrease in the apparent amount of the molecules but
not in their distribution, our immunocytochemical results with
MFas II both in vivo and in vitro suggest that its presence on ORN
axons was significantly reduced. Our culture experiments suggest
that MFas II is rarely associated with WGA-labeled membrane
domains, but the Vybrant DiI-WGA co-labeling experiments
suggest the presence of another class of gMSDs with which the
MFas II could be associated. The sucrose gradient flotation
experiments, in which TM-Fas II was found primarily in Triton-
resistant fractions, support this scenario. Rafts are known to be one
of a variety of mechanisms used in the transport of certain
molecules along axons [22,133–135], but some of these molecules,
neuroglian for example, appear to have access to multiple
mechanisms of axon transport [136] and thus would continue to
be transported after MbCD treatment. Perhaps TM-MFas II
depends solely on raft-like membrane domains for transport and
thus would become depleted in the face of MbCD treatment.
Summary
In previous studies, we have shown that both axon-axon and
axon-glia interactions operate at several points in the developing
olfactory pathway to ensure that ORN axons sort, form fascicles,
and navigate toward their correct glomerular target, and that
glomerulus construction and stabilization proceed properly. The
results of studies of IgCAM-RTK-cytoskeleton interactions in both
vertebrate and invertebrate systems suggest that binding between
L1/neuroglian molecules in trans and in cis results in EGFR
activation via a ligand-independent mechanism which in turn
stabilizes the neuroglian, presumably by activating a pathway that
links it to the cytoskeleton. The current results in the M sexta
olfactory pathway indicate that many EGFRs are distributed
within membrane subdomains and that both EGFR activation and
neuroglian stabilization are reduced when these subdomains are
disrupted. Removal of membrane sterols by treatment with
MbCD affects ORN axon growth and fasciculation in the sorting
zone region of the antennal nerve, affects the organization and
distribution of glomeruli, and allows axon terminal branches to
extend beyond their glomerular territory, at least in a subset of
ORN axons. Together, the results are consistent with a functional
link between EGFR activation and neuroglian stabilization,
possibly mediated by their clustering in GSL-rich membrane
subdomains. In addition, the results require that any model of the
primary and downstream interactions occurring in this system take
into account both the dynamic nature of gMSD-based interactions
and the molecular players likely to be associated with these
subdomains. It is not yet clear whether the role of the subdomains
in modulating the neuroglian-EGFR interaction is to facilitate
translation of EGFR activity into activation of downstream
pathways or whether they play a direct role in mediating
neuroglian-neuroglian and/or neuroglian-EGFR interactions.
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